InspireMD Announces Positive Results from iMOS Prime Registry for the MGuard Prime EPS

[PR Newswire] – BOSTON, May 7, 2014 /PRNewswire/ — InspireMD, Inc. (InspireMD or the Company) (NYSE MKT: NSPR), a leader in embolic protection stents (EPS), today announced new results from the iMOS (International MGuard Observational Study) Prime Regis more

View todays social media effects on NSPR

View the latest stocks trending across Twitter. Click to view dashboard

See who InspireMD is hiring next, click here to view